A new method using 454 sequencing has identified significant human genetic variation, including structural variations that play a crucial role in genetic diversity. The study found over 1000 structural variations in two individuals and suggests that these variations may have notable physical effects on an individual.
A novel method for sequencing ancient DNA has been developed using the Genome Sequencer FLX system, enabling researchers to study extinct animals with unprecedented accuracy. The technique involves extracting DNA from hair shafts, which are more undamaged and uncontaminated than traditional samples.
Researchers used 454 sequencing to analyze messenger RNA from wasp brains, correlating expression patterns with social behaviors. Insulin-related genes showed distinct patterns, suggesting eusociality involves major nutritional and reproductive pathways.
The collaboration reveals that modern human and Neandertal DNA sequences diverged on average about 500,000 years ago. The sequencing team aims to reconstruct a draft of the 3 billion bases that made up the genome of Neandertals, shedding light on human biology.
Research reveals ARGONAUTE 4 protein (AGO4) plays a dual role in RNA-directed DNA methylation, controlling epigenetic organization of entire genome. 454 Sequencing technology allows for comprehensive view of small RNAs, revolutionizing research on mechanisms of RNA interference.
The study used 454 Sequencing to analyze EGFR gene mutations in lung cancer tumors, detecting genetic variations that can predict patient responsiveness to treatment with EGFR inhibitors. The technology enables accurate molecular diagnosis and may facilitate targeted therapies.
Researchers found significant genomic rearrangements in human and non-human primate DNA, suggesting a new source of variation between species. These findings may provide insights into human health and disease, and could inform targeted investigations of gene expression differences.
Researchers have gained a new understanding of how quinoline-based drugs work against the Malaria parasite, slowing crystal growth to toxic levels and killing the parasite. The study provides insights into physical chemistry and crystalline surface structure to explain drug action, offering potential solutions to drug resistance.
A clinical trial using fMRI found that secretin activates the amygdala, a brain region involved in social integration and implicated in autism. The study suggests that secretin may have a role in modulating certain social behaviors in humans.
Vitex's INACTINE technology demonstrated complete parasite eradication of Trypanasoma cruzi, Plasmodium falciparum, and Babesia microti parasites. The company's pathogen reduction system meets critical requirements for commercial success, with potential to improve safety of red blood cell transfusions.
A survey found that few Americans are aware of ocular hypertension, with only 41% recognizing it as a factor in glaucoma risk. Many individuals over 40 years old are unaware they need routine screening for the condition, despite being at increased risk.
BP7787 shows impressive safety profile and high tumor response rate, indicating potential as a preventive measure for chemotherapy side effects. The Phase 1 clinical trial demonstrated no severe nerve damage and partial tumor remission in nearly all patients treated with BNP7787
Researchers analyzed muscle biopsies from patients with polymyositis and sarcoid myopathy to identify key cell surface receptors involved in T-cell adhesion and migration. The study used MelTec's MELK technology to map protein networks in whole, intact cells, providing new insights into disease mechanisms.
A team at Cellzome developed a novel approach to systematically use protein interaction maps in drug discovery, enabling researchers to better assess protein roles and predict drug effects. The yeast proteomic map provides a framework for integrating data from literature and experiments.
Results from two independent studies show omega interferon's antiviral effect against all HCV genotypes, reducing virus to undetectable levels. The treatment also appeared to be well-tolerated by patients, with progressive anti-hepatitis C effects reported.
Researchers from SurroMed and Penn State University have developed Nanobarcodes particles, which can identify individual particles using optical microscopy. This technology enables multiplexed bioassays in solution, revolutionizing life science research and disease diagnosis.
The collaboration between Myriad Genetics and the University of Utah revealed that the Tsg101 protein is essential for HIV1 budding, allowing for the disruption of the virus lifecycle. This breakthrough led to the identification of potential HIV drug targets, with lead compounds developed for anti-HIV therapy.
Agenerase ™ demonstrates promising once-daily dosing results, allowing for simplified HIV therapy. The amprenavir prodrug, VX-175, offers significant simplification of protease inhibitor-based treatment by enabling daily dosing of just two or three pills.
Idun Pharmaceuticals recreates key apoptosis reaction to understand mechanism of programmed cell death. The company screens new drugs modulating apoptosis using the assay, aiming to treat cancers, heart attacks, and strokes.
SEQUENOM successfully validated the largest collection of gene-based SNPs to date, identifying 3,148 previously unknown SNPs. The company's MassARRAY system enabled rapid and high precision SNP allele frequency determination in pooled DNA samples.
Phase II studies indicate that Mylovenge causes regression or stabilization in over 30% of patients with multiple myeloma and amyloidosis, with some benefits lasting up to 18 months. The vaccine stimulates the immune system to recognize and destroy cancer cells.
Researchers at Dendreon Corporation have developed a method for generating enhanced immune responses with potentially important implications for therapeutic cancer vaccines. The approach involves modifying antigens to optimize uptake and processing by dendritic cells, resulting in significant cytotoxic T-cell activity.
Researchers at Rosetta Inpharmatics used high-quality gene expression data and computational methods to identify novel gene functions. The company's approach enables the deciphering of previously uncharacterized genes, with applications in new drug discovery and development.
Researchers at Rosetta Inpharmatics used Flexjet DNA microarray technology to analyze the role of changes in chromosome number on gene expression, showing large-scale biases that affect cellular processes. The study provides a novel tool for evaluating aneuploidy and its potential applicability to human cancer cells.
A Phase I study of aerosolized administration of tgAAV-CF showed efficient gene transfer throughout the upper airways of patients with mild CF lung disease. No neutralizing antibodies were detected, suggesting a good safety profile for further development.
Targeted Genetics Corporation has shown promise in its AAV gene therapy program for rheumatoid arthritis (RA), reducing ankle and hind paw swelling in preclinical studies. The treatment uses a recombinant TNFR:Fc fusion protein, which antagonizes the function of TNF-a, a key component of the inflammatory response.
Introgen presents Phase I trial results on RPR/INGN 201, showing safety and expression in ovarian cancer, lung carcinoma, and glioblastoma patients. The therapy has demonstrated significant potential in treating these life-threatening conditions.
Abarelix depot-M successfully suppresses testosterone levels, achieving suppression by day 8 and maintaining it from day 29 through day 85. The studies validated PRAECIS' core technology and demonstrate a potentially new treatment option for prostate cancer.
The company presented Phase II data of tgDCC-E1A, a lead cancer therapy, which showed a 45% objective response rate in patients with recurrent head and neck squamous cell carcinoma. Preclinical studies also demonstrated the ability of E1A to sensitize tumors to radiation and chemotherapy.
Researchers conducted a Phase II trial of adenoviral p53 gene transfer with radiation therapy, showing 29% of patients achieved local tumor control and 12 of 15 had no active cancer. The study demonstrated considerable promise for combined treatments, comparing favorably to a control rate of less than 20% in patients treated with radia...
Researchers at Johns Hopkins presented Phase I study results for Taxoprexin DHA-paclitaxel, a novel taxane that tolerates high doses with minimal side effects. The drug delivers more therapeutic agent to tumor cells and less to healthy tissues, improving safety and effectiveness.
Researchers at ZymoGenetics developed a novel immunosuppressive agent that inhibits disease symptoms in mouse models of systemic lupus erythematosus (SLE). The treatment works by capturing a cytokine that stimulates B cells to make antibodies, reducing their destructive impact on the body.
Researchers at Advanced Cell Technology successfully reversed the aging process in cells, potentially leading to treatments for age-related diseases. The breakthrough involves using cloning technology to reset the cellular clock, allowing cells to divide indefinitely.
BioNumerik reports success with its engineered cancer agents, demonstrating reduced toxicity while preserving antitumor activity. The company plans to initiate Phase 3 trials for BNP7787 and expand clinical trials for Karenitecin BNP1350.
Researchers at Yale and Alexion discovered harmful complement activation in patients with acute coronary syndrome, increasing the risk of cardiovascular disease. The study found that activated complement levels increased by up to 70% in ACS patients' hearts, compared to 16% in stable angina patients.
Researchers used genomics-based approach to discover new surface proteins that behave differently and are present across multiple strains of Neisseria meningitidis. These proteins can stimulate an antibody response capable of killing the bacterium, a key property for vaccine efficacy.
The Keck Graduate Institute will host a workshop on post-baccalaureate alternatives for science and math majors, exploring new M.S. professional degrees in the biosciences. The program aims to equip students with promising career opportunities in pharmaceuticals, biotechnology, and medical industries.
The companies identified a family of proteins called Potassium Channel Interacting Proteins (KChIPs) that regulate A-type potassium channels, which control brain electrical signals. These KChIPs may lead to the development of new therapeutics for CNS disorders with minimal side effects.
Researchers found Madh6 gene and Smad6 protein play crucial role in cardiovascular system, causing heart valve and blood vessel abnormalities. This discovery provides potential target for developing novel therapies to treat cardiovascular disease.
Rheumatoid arthritis patients receiving a single dose of Alexion's 5G1.1 showed significant reduction in joint pain and symptoms compared to placebo-treated patients, with 50% achieving an ACR20 score. The company is currently enrolling up to 200 patients in a Phase II efficacy trial employing multiple doses of 5G1.1.
Scientists at Millennium and the Whitehead Institute discovered a novel protein FATP4 that plays a role in transporting fatty acid molecules from the intestine into the body. Inhibiting its function may provide new approaches to treating obesity.
Researchers identify nephrin's role in the kidney's filtration barrier, finding a 'zipper-like' structure that allows blood to pass but not plasma proteins. Increasing nephrin production or restoring its function is thought to improve kidney function and restore proteinuria.
The report in Science reveals the x-ray crystal structure of MMP-2, a key target for anti-cancer drug candidates. The elucidated structure provides valuable information on the function and regulation of MMP-2, enabling the design of improved inhibitors.
Research finds that noncompliance with prescribed antihypertensive drugs leads to approximately half of the failures in controlling high blood pressure. A special electronic medication container, eDEM Monitor, identifies clinically unrecognized noncompliance.
Abgenix's Phase II trial shows 56% of patients survived at least 100 days with high-dose ABX-CBL, outperforming low-dose cohort. The company plans a pivotal Phase III clinical trial for ABX-CBL after FDA approval.
The American Red Cross has developed a new genetic test, nucleic acid testing (NAT), to detect viruses such as HIV and Hepatitis C Virus (HCV) in blood donations. This technology can identify infectious agents earlier than current screening tests, reducing the risk of disease transmission through blood products.
ABX-EGF targets the receptor for human epidermal growth factor (EGFr), which is overexpressed on many major human tumor types. The antibody eradicates established tumors with low doses and has minimal immunogenicity.
Researchers at Millennium Pharmaceuticals have cloned the mahogany gene, which produces a protein that can suppress diet-induced obesity in mice. The study found that mice with a mutated mg gene maintain a healthy weight on both high-fat and low-fat diets, suggesting a similar role in humans.
Researchers at Allelix Biopharmaceuticals Inc. have successfully cloned the GLP-2 receptor, which plays a crucial role in intestinal growth and nutrient absorption. The discovery provides valuable information on the specificity and action of GLP-2, a potential therapy for gastrointestinal disorders such as short bowel syndrome.
Clinical trials show substantial increase in leukemia-free survival among AML patients treated with Maxamine Therapy. The treatment has been shown to prevent relapse and prolong remission while maintaining a good quality of life.